Abstract
United States Nephrology & Urology Devices Medical Equipment Industry
Report
Summary
This report is an essential source for in-depth information and data relating
to United States Nephrology & Urology devices medical equipment market. It
also offers detailed and comprehensive coverage of market revenue, volume,
distribution and company share information; and latest news, financial deals
and pipeline products information of each of the key sub-segments of the
Nephrology & Urology devices medical equipment in United States.
Scope
・ The report provides sector information broken down into detailed categories
and segments in country.
・ Total revenues, products sold, end users, and
average pricing.
・ Market shares of all the key competitors.
・ Key
pipeline products that are set to shape the market, broken down by sector.
・ Information on the top medical equipment companies in the sector in the
country covering business description, strategic analysis, and financial
information.
・ Healthcare structure, regulatory environment, approval
process, pricing trends and reimbursement.
・ Product and brand updates,
strategy changes, R&D projects, corporate expansions and contractions and
regulatory changes.
・ Key mergers and acquisitions, partnerships, private
equity investments and IPOs.
・ Customer, hospitals and physicians
data.
Note: Some content types may not be available in this report
Reasons to buy
・ Gain a strong understanding of the industry at a global level, with break
downs for the country
・ Evaluate and compare the attractiveness of the
market in the country.
・ Identify growth segments and opportunities in
each industry sector within the country.
・ Evaluate the pipeline of key
products that will change the sector, and identify threats and opportunities
before the products are launched in the country.
・ Analyze the
competitiveness of the market in the country and identify hotspots.
・
Develop strategies based on the latest product, brand, expansion and research
and development news in the country.
・ Do deals with an understanding of
how competitors are financed, and the mergers and partnerships that have
shaped the market in the country.
・ Identify and analyze the strengths and
weaknesses of the industry incumbents in the country.
Table of Contents
Table of Contents
1 Table Of Contents 2
1.1 List of Tables 12
1.2 List of Figures 16
2 Introduction 19
2.1 What Is This Report
About? 19
2.2 Definitions 19
2.2.1 Nephrology and Urology Devices
19
3 Healthcare Sector Review 22
3.1 Healthcare Expenditure 22
3.2
Healthcare Infrastructure 27
3.2.1 Healthcare Personnel Data 29
3.2.2
Healthcare Facilities Data 32
4 Nephrology and Urology Devices in United
States 34
4.1 Nephrology and Urology Devices Overall Revenues (2000-2012)
34
4.2 Nephrology and Urology Devices Overall Volume (2000-2012) 39
4.3 Nephrology and Urology Devices Overall Company Share (2005-2006) 41
5
Incontinence Devices in United States 43
5.1 Incontinence Devices Overall
Revenue (2000-2012) 43
5.1.1 Protective Garments for Incontinence Overall
Revenues (2000-2012) 47
5.1.2 Urinary Catheters Overall Revenues
(2000-2012) 50
5.1.3 Urine Bags Overall Revenues (2000-2012) 52
5.2
Incontinence Devices Overall Volume (2000-2012) 54
5.2.1 Protective
Garments for Incontinence Overall Volume (2000-2012) 56
5.2.2 Urine Bags
Overall Volume (2000-2012) 58
5.2.3 Urinary catheters Overall Volume
(2000-2012) 60
5.3 Incontinence Devices Average Price (2000-2012) 62
5.3.1 Protective Garments for Incontinence Average Price (2000-2012) 62
5.3.2 Urinary Catheters Average Price (2000-2012) 64
5.3.3 Urine Bags
Average Price (2000-2012) 66
5.4 Incontinence Devices Distribution Share
(2005-2006) 68
5.4.1 Incontinence Devices Company Share 69
6 Renal
Dialysis in United States 70
6.1 Renal Dialysis Equipment Overall Revenue
(2000-2012) 70
6.1.1 Peritoneal Dialysis Solutions Overall Revenues
(2000-2012) 74
6.1.2 Hemodialysis Machines Overall Revenues (2000-2012)
76
6.1.3 Continuous Renal Replacement Therapy Machines Overall Revenues
(2000-2012) 78
6.1.4 Dialysis Accessories Overall Revenues (2000-2012)
80
6.2 Renal Dialysis Equipment Overall Volume (2000-2012) 92
6.2.1
Dialysis Accessories Overall Volume (2000-2012) 93
6.2.2 Continuous Renal
Replacement Therapy Machines Overall Volume (2000-2012) 105
6.2.3
Hemodialysis Machines Overall Volume (2000-2012) 107
6.3 Renal Dialysis
Equipment Average Price (2000-2012) 109
6.3.1 Hemodialysis Machines
Average Price (2000-2012) 109
6.3.2 Continuous Renal Replacement Therapy
Machines Average Price (2000-2012) 111
6.3.3 Dialysis Accessories Average
Price (2000-2012) 113
6.4 Renal Dialysis Equipment Distribution Share
(2005-2006) 123
6.5 Renal Dialysis Equipment Company Share (2005-2006)
124
7 Lithoripters in United States 125
7.1 Lithotripters Overall
Revenue (2000-2012) 125
7.2 Lithotripters Overall Volume (2000-2012)
127
7.3 Lithotripters Average Price (2000-2012) 129
7.4 Lithotripters
Distribution Share (2005-2006) 131
7.5 Lithotripters Company Share
(2005-2006) 132
8 Baxter International Company Profile 133
8.1
Company Overview 133
8.2 Business Overview 133
8.2.1 BioScience
133
8.2.2 Medication Delivery 133
8.2.3 Renal 134
8.2.4 Products
134
8.2.5 History 135
8.3 Value Chain Analysis 138
8.3.1
Manufacturing 138
8.3.2 Product Development 138
8.3.3 Sales and
Marketing 139
8.4 SWOT Analysis 140
8.4.1 Baxter International Inc.
Strengths 140
8.4.2 Baxter International Inc. Weaknesses 141
8.4.3
Baxter International Inc. Opportunities 141
8.4.4 Baxter International
Inc. Threats 141
8.5 Financial and Operational Review 142
8.6
Locations And Subsidiaries 143
8.7 Financial Deals Landscape 146
8.7.1
Baiyunshan And Baxter Form A Joint Venture In China 146
8.7.2 Baxter Signs
Licensing Agreement With Intercytex And Spinal Restoration 147
8.7.3
Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick
Capital 149
8.7.4 B. Braun Acquires Renal Therapy Business Of Baxter
151
8.7.5 Innovata signs a license agreement with Baxter International
152
8.7.6 Kuros Biosurgery Signs An Agreement With Baxter International
154
8.7.7 Gambro Signs An Agreement With Baxter 155
8.7.8 Baxter
Healthcare And Gambro Enter Into An Agreement 157
8.7.9 Baxter and Cerus
Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood
System 159
8.7.10 Baxter International And Kaketsuken Enter Into Agreement
160
8.7.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest
Treeful 162
8.8 Recent Developments 163
8.8.1 Jan 24, 2008: Baxter
Achieves Record Sales and Earnings for Full-Year 2007 163
8.8.2 Dec 18,
2007: Baxter Elects CFO 165
8.8.3 Nov 13, 2007: Baxter Declares Quarterly
Dividend 165
8.8.4 Aug 01, 2007: Baxter Elects New Board Director 165
8.8.5 Jul 31, 2007: Baxter Announces Quarterly Dividend 166
8.8.6 Mar 13,
2007: Baxter Declares Additional Share Repurchase Authorization 166
8.8.7
Feb 13, 2007: Baxter Announces Quarterly Dividend 166
8.8.8 Nov 28, 2006:
Baxter Announces Annual Dividend 167
8.8.9 Sep 14, 2006: Baxter Appoints
President, Baxter Latin America 167
8.9 Baxter International Inc. Pipeline
Products 168
8.9.1 Next-Generation Home Hemodialysis Machine 168
9
Kimberly-Clark Corporation Company Profile 169
9.1 Company Overview
169
9.2 Business Overview 169
9.2.1 Consumer Tissue 169
9.2.2
Healthcare 169
9.2.3 K-C Professional & Other 170
9.2.4 Personal Care
170
9.2.5 Products 171
9.2.6 History 171
9.3 Value Chain Analysis
174
9.3.1 Manufacturing 174
9.3.2 Product Development 175
9.3.3
Sales and Marketing 175
9.4 SWOT Analysis 175
9.4.1 Kimberly-Clark
Corporation Strengths 176
9.4.2 Kimberly-Clark Corporation Weaknesses
176
9.4.3 Kimberly-Clark Corporation Opportunities 177
9.4.4
Kimberly-Clark Corporation Threats 177
9.5 Financial and Operational
Review 178
9.6 Locations And Subsidiaries 179
9.7 Financial Deals
Landscape 181
9.7.1 Kimberly-Clark Increases Its Ownership In Brazilian
Affiliate To 100% 181
9.7.2 Kimberly-Clark Acquires Microcuff 182
9.7.3 Betty Mills Partners with Kimberly-Clark Professional 182
9.8 Recent
Developments 184
9.8.1 Mar 06, 2008: Kimberly-Clark Announces Management
Changes 184
9.8.2 Feb 21, 2008: Kimberly-Clark Approves Quarterly Dividend
184
9.8.3 Nov 14, 2007: Kimberly-Clark Declares Quarterly Dividend 184
9.8.4 Aug 01, 2007: Kimberly-Clark Declares Quarterly Dividend 185
9.8.5
Jul 25, 2007: Kimberly-Clark Elects New Board Member 185
9.8.6 Apr 26,
2007: Kimberly-Clark Declares Quarterly Dividend 185
9.8.7 Apr 02, 2007:
Kimberly-Clark Announces New Global Marketing Structure 185
9.8.8 Mar 19,
2007: Kimberly-Clark Announces President 187
9.8.9 Feb 21, 2007:
Kimberly-Clark Announces Increase In Dividend 187
9.8.10 Feb 15, 2007:
Kimberly-Clark Announces CIO 188
9.8.11 Jan 29, 2007: Kimberly-Clark Signs
Agreement With Accenture 188
9.8.12 Jan 16, 2007: Kimberly-Clark Signs
Agreement With Cognizant 189
9.8.13 Jan 16, 2007: Kimberly-Clark Signs
Agreement With TCS 189
9.8.14 Jan 08, 2007: Kimberly-Clark Signs Agreement
With ICG Commerce 190
9.8.15 Jan 08, 2007: Kimberly-Clark Signs Contract
With Genpact 190
9.8.16 Nov 15, 2006: Kimberly-Clark Elects Board Member
191
9.8.17 Nov 15, 2006: Kimberly-Clark Declares Quarterly Dividend
191
9.8.18 Sep 21, 2006: Kimberly-Clark Announces CMO 191
9.8.19 Sep
20, 2006: Kimberly-Clark To Establish Innovation Center In South Korea 192
9.8.20 Aug 01, 2006: Kimberly-Clark Declares Quarterly Dividend 193
10
Covidien Ltd./Tyco Healthcare Company Profile 194
10.1 Company Overview
194
10.2 Business Overview 194
10.2.1 Imaging Solutions 194
10.2.2
Medical Devices 195
10.2.3 Medical Supplies 195
10.2.4 Pharmaceutical
Products 196
10.2.5 Retail Products 196
10.2.6 Major Products and
Services 197
10.2.7 History 197
10.3 Value Chain Analysis 198
10.3.1 Manufacturing 199
10.3.2 Product Development 199
10.3.3 Sales
and Marketing 200
10.4 SWOT Analysis 201
10.4.1 Covidien Ltd./Tyco
Healthcare Strengths 201
10.4.2 Covidien Ltd./Tyco Healthcare Weaknesses
202
10.4.3 Covidien Ltd./Tyco Healthcare Opportunities 203
10.4.4
Covidien Ltd./Tyco Healthcare Threats 203
10.5 Financial and Operational
Review 205
10.5.1 Financial Statements 205
10.5.2 Financial Ratios
206
10.5.3 Share Holding Structure 207
10.6 Locations And Subsidiaries
207
10.7 Financial Deals Landscape 209
10.7.1 Covidien Signs An
Agreement With Allergan 209
10.7.2 Covidien Acquires Scandius Biomedical
210
10.7.3 Covidien International Finance Completes Private Placement Of
$2,750 Million 211
10.7.4 Covidien And BioSynthema Enter Into Licensing
Agreement 213
10.7.5 Integra LifeSciences Acquires Assets Of Radionics
Division From Covidien 214
10.7.6 Covidien To Sell European Incontinence
Business 216
10.7.7 Covidien To Acquire Tissue Science Laboratories
218
10.8 Recent Developments 220
10.8.1 Mar 28, 2008: Covidien Spends
$760,000 Lobbying Federal Government In 2007 220
10.8.2 Mar 18, 2008:
Covidien Declares Quarterly Dividend 220
10.8.3 Feb 21, 2008: Covidien
Gests Favorable Decision In Patent Litigation Case 220
10.8.4 Feb 07,
2008: Covidien Declares Q1 Fiscal 2008 Results 220
10.8.5 Jan 15, 2008:
Covidien Declares Quarterly Dividend 222
10.8.6 Jan 10, 2008: Covidien To
Declare Q1 Fiscal 2008 Results 222
10.8.7 Dec 06, 2007: Covidien Reports
Q4 Fiscal 2007 Results 222
10.8.8 Oct 04, 2007: Covidien And NewSouth
Innovations Collaborate To Develop Novel Imaging Agent 224
10.8.9 Sep
28, 2007: Covidien Declares Quarterly Dividend 225
10.8.10 Aug 09, 2007:
Covidien Declares Q3 Fiscal 2007 Results 225
10.9 Covidien Ltd./Tyco
Healthcare Pipeline Products 226
10.9.1 PleuraSeal Lung Sealant System
226
10.9.2 Sandman Intro CPAP Device 227
11 C.R. Bard, Inc. Company
Profile 229
11.1 Company Overview 229
11.2 Business Overview 229
11.2.1 Oncology Product Line 229
11.2.2 Other Products Product Line
229
11.2.3 Surgical Specialties Product Line 229
11.2.4 Urology
Product Line 230
11.2.5 Vascular Product Line 230
11.2.6 Major
Products and Services 230
11.2.7 History 231
11.3 Value Chain Analysis
233
11.3.1 Manufacturing 234
11.3.2 Product Development 234
11.3.3
Sales and Marketing 235
11.4 SWOT Analysis 235
11.4.1 C.R. Bard, Inc.
Strengths 236
11.4.2 C.R. Bard, Inc. Weaknesses 237
11.4.3 C.R. Bard,
Inc. Opportunities 237
11.4.4 C.R. Bard, Inc. Threats 238
11.5
Financial and Operational Review 239
11.5.1 Financial Statements 239
11.5.2 Financial Ratios 240
11.5.3 Share Holding Structure 241
11.6
Locations And Subsidiaries 241
11.7 Financial Deals Landscape 244
11.7.1 Edwards Lifesciences Sells LifeStent Product Line to C.R. Bard 244
11.7.2 C. R. Bard Enters Into License Agreement With Genzyme Corporation
245
11.7.3 Bard Acquires Venetec International 247
11.7.4 Bard
Acquires Stent Technology Assets From PST 248
11.7.5 Bard Acquires Certain
Assets From Genyx Medical 250
11.7.6 CONMED Acquires Endoscopic
Technologies Product Line From C.R. Bard 251
11.7.7 C. R. Bard Acquires
Assets Of Onux Medical 253
11.7.8 Tissue Science Laboratories Enters Into
Agreement With C.R. Bard 254
11.7.9 C. R. Bard To Acquire Specialized
Health Products International 255
11.8 Recent Developments 257
11.8.1
Jan 31, 2008: Bard Reports Q4 2007 Results 257
11.8.2 Dec 12, 2007: Bard
Announces Patent Infringement Verdict Against W. L. Gore 258
11.8.3 Dec
12, 2007: Bard Declares Quarterly Dividend 258
11.8.4 Oct 23, 2007: Bard
Reports Q3 2007 Results 258
11.8.5 Oct 10, 2007: Bard Announces Share
Repurchase Program 259
11.8.6 Oct 10, 2007: Bard Declares Quarterly
Dividend 259
11.8.7 Jul 24, 2007: Bard Reports Q2 2007 Results 260
11.8.8 Jun 13, 2007: Bard Declares Quarterly Dividend 261
11.8.9 Apr 24,
2007: Bard Reports Q1 2007 Results 261
11.8.10 Apr 18, 2007: Bard Declares
Quarterly Dividend 261
11.8.11 Jan 25, 2007: Bard Reports Q4 2006 Results
262
11.9 C.R. Bard, Inc. Pipeline Products 263
11.9.1 VIVEXX Carotid
Stent 263
11.9.2 Bard Pulsed RF Ablation System 265
11.9.3 BARD HD
MESH Ablation System 267
11.9.4 Bard Scorpion Ablation Catheter 267
11.9.5 BARD HD MESH Mapper Catheter 268
12 Fresenius Medical Care AG & Co.
KGaA Company Profile 269
12.1 Company Overview 269
12.2 Business
Overview 269
12.2.1 Dialysis Care Segment 269
12.2.2 Dialysis Products
Segment 270
12.2.3 Major Products and Services 271
12.2.4 History
271
12.3 Value Chain Analysis 273
12.3.1 Manufacturing 273
12.3.2
Product Development 274
12.3.3 Sales and Marketing 274
12.4 SWOT
Analysis 275
12.4.1 Fresenius Medical Care AG & Co. KGaA Strengths 275
12.4.2 Fresenius Medical Care AG & Co. KGaA Weaknesses 276
12.4.3
Fresenius Medical Care AG & Co. KGaA Opportunities 277
12.4.4 Fresenius
Medical Care AG & Co. KGaA Threats 277
12.5 Financial and Operational
Review 279
12.5.1 Financial Statements 279
12.5.2 Financial Ratios
280
12.6 Locations And Subsidiaries 281
12.7 Financial Deals Landscape
281
12.7.1 Fresenius Medical Acquires Renal Solutions 281
12.7.2
Fresenius Medical Care Completes Private Placement 283
12.7.3 Fresenius
Completes Acquisition Of The Phosphate Binder Business From Nabi
Biopharmaceuticals 284
12.7.4 Fresenius Medical Care Acquires Renal Care
Group 285
12.8 Recent Developments 287
12.8.1 Mar 06, 2008: Fresenius
Expands Dialyzer Production Capacity In Germany 287
12.8.2 Feb 20, 2008:
Fresenius Medical Declares Q4 2007 Results 288
12.8.3 Oct 31, 2007:
Fresenius Medical Declares Q3 2007 Results 290
12.8.4 Aug 02, 2007:
Fresenius Medical Declares Q2 2007 Results 290
12.8.5 May 15, 2007:
Fresenius Medical Announces Share Split Approval 292
12.8.6 May 02, 2007:
Fresenius Medical Declares Q1 2007 Results 292
12.8.7 Feb 22, 2007:
Fresenius Medical Declares Q4 2006 Results 292
12.8.8 Oct 31, 2006:
Fresenius Medical Declares Q3 2006 Results 294
13 Regulation System
295
13.1 Medical Equipment Approval Process 295
13.1.1 Pre-market
Approval Process 296
13.1.2 Intended use and Indications for use 296
13.1.3 Predicate Device 296
13.1.4 Safe and Effective 297
13.1.5 Other
Category Devices 299
13.1.6 Post-Market Approval Process 300
13.1.7
Compliance and Enforcement 300
13.1.8 Registration Fee 301
13.1.9
Approval Time 301
14 Pricing and Reimbursement 302
14.1 Government
Policies 302
14.2 Private Insurance 303
14.3 Diagnosis Related Groups
(DRG) 304
15 Distribution Structure 305
15.1 Distribution Structure
305
16 APPENDIX 306
16.1 Methodology 306
16.2 Coverage 307
16.3 Secondary Research 307
16.4 Primary Research 308
16.5 Models
308
16.6 Forecasts 309
16.7 Expert Panels 309
16.8 Contact Us
310
16.9 Disclaimer 310
